Inspire(US:INSP) Businesswire·2025-11-18 17:10Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor performance of its new sleep apnea device, Inspire V, which has been delayed in launch and has seen poor demand [2][4]. - The company significantly reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [2][3]. Company Performance - On August 4, 2025, Inspire disclosed issues with the launch of Inspire V, including inadequate training for treatment centers, software update delays, and excess inventory leading to poor demand [2][4]. - Following the announcement, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share on August 5, 2025, impacting investors negatively [3]. Legal Proceedings - The class action lawsuit alleges that the company made materially false and misleading statements regarding its business operations and prospects during the class period from August 6, 2024, to August 4, 2025 [4][5]. - Investors who purchased Inspire common stock during the class period are encouraged to file a lead plaintiff motion by January 5, 2026 [5].